Division of Health Economics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
J Gastrointest Cancer. 2023 Jun;54(2):391-407. doi: 10.1007/s12029-022-00821-3. Epub 2022 Apr 26.
Pancreatic cancer is characterized by its high mortality, usually attributed to its diagnosis in already advanced stages. This article aims at presenting an overview of the economic burden of pancreatic cancer in Europe.
A systematic literature review was conducted. It made use of the search engines EconLit, Google Scholar, PubMed and Web of Science, and retrieved articles published after December 31st, 1992, and before April 1st, 2020. Study characteristics and cost information were extracted. Cost per patient and cost per patient per month (PPM) were calculated, and drivers of estimate heterogeneity was analysed. Results were converted into 2019 Euros.
The literature review yielded 26 studies on the economic burden attributable to pancreatic cancer in Europe. Cost per patient was on average 40,357 euros (median 15,991), while figures PPM were on average 3,656 euros (median 1,536). Indirect costs were found to be on average 154,257 euros per patient or 14,568 euros PPM, while direct costs 20,108 euros per patient and 2,004 euros PPM. Nevertheless, variation on cost estimations was large and driven by study methodology, patient sample characteristics, such as type of tumour and cancer stage and cost components included in analyses, such as type of procedure.
Pancreatic cancer direct costs PPM are in the upper bound relative to other cancer types; however, direct per patient costs are likely to be lower because of shorter survival. Indirect costs are substantial, mainly attributed to high mortality.
胰腺癌的死亡率很高，通常归因于其在晚期被诊断出来。本文旨在概述欧洲胰腺癌的经济负担。
进行了系统的文献回顾。它使用了 EconLit、Google Scholar、PubMed 和 Web of Science 搜索引擎，检索了 1992 年 12 月 31 日以后和 2020 年 4 月 1 日以前发表的文章。提取了研究特征和成本信息。计算了每位患者的成本和每位患者每月的成本（PPM），并分析了估计异质性的驱动因素。结果转换为 2019 年欧元。
文献综述共检索到 26 项关于欧洲归因于胰腺癌的经济负担的研究。每位患者的平均成本为 40357 欧元（中位数 15991 欧元），而 PPM 的平均数字为 3656 欧元（中位数 1536 欧元）。发现每位患者的间接成本平均为 154257 欧元或 PPM 为 14568 欧元，而直接成本为每位患者 20108 欧元或 PPM 为 2004 欧元。然而，成本估计的差异很大，主要是由研究方法、患者样本特征（如肿瘤类型和癌症阶段）以及分析中包含的成本组成部分（如手术类型）驱动的。
胰腺癌直接 PPM 成本相对于其他癌症类型处于较高水平；然而，由于生存时间较短，每位患者的直接成本可能较低。间接成本很高，主要归因于高死亡率。
